Additionally, we assessed the glycemic and plasma hormone responses to SSTR2 antagonists under basal and meal-simulated conditions using an oral glucose tolerance test (OGTT) to better understand their therapeutic potential for people living with T2D. The gene discussed is SSTR2; the disease is type 2 diabetes mellitus.